CLS receives new order for single use products from UTMB in the U.S., for treatment of early stage prostate cancer
Clinical Laserthermia Systems (CLS) (publ), has, through its subsidiary CLS Americas Inc., received yet another order for for CLS’s sterile single use products, for MRI-guided focal laser ablation, from the University of Texas Medical Branch (UTMB). The order value amounts to about 400 000 SEK. - UTMB continues to choose our products for treatment of patients with early stage prostate cancer, or other tumor disease, in the prostate. UTMB has become an important reference for us in the USA-market and the collaboration with the hospital continues to develop in a positive way, says Dan